Drug Type Small molecule drug |
Synonyms |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), Lipid modulators, Triglyceride modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS Registry344423-98-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 3 | - | 04 May 2016 |
NCT03482180 (Pubmed) Manual | Phase 3 | 200 | Atorvastatin+Atorvastatin/Omega-3-Acid Ethyl Esters | (gkhfcbmrct) = rcafccarpw zarjdlgrjs (bnblfeyici ) View more | Positive | 01 Feb 2020 | |
Atorvastatin+Placebo | (gkhfcbmrct) = laixtbhzcy zarjdlgrjs (bnblfeyici ) View more |